Uric acid-lowering treatment with benzbromarone in patients with heart failure a double-blind placebo-controlled crossover preliminary study

Kazuhide Ogino, Masahiko Kato, Yoshiyuki Furuse, Yoshiharu Kinugasa, Katsunori Ishida, Shuichi Osaki, Toru Kinugawa, Osamu Igawa, Ichiro Hisatome, Chiaki Shigemasa, Stefan D. Anker, Wolfram Doehner

Research output: Contribution to journalArticlepeer-review

Abstract

Background-Hyperuricemia is common in chronic heart failure (CHF), and it is a strong independent marker of prognosis. Upregulated xanthine oxidase (XO) activity and impaired renal excretion have been shown to account for increased serum uric acid (UA) levels in CHF. Therapeutic interventions with allopurinol to reduce UA levels by XO inhibition have been shown to be beneficial. Discussions are ongoing whether UA itself is actively involved or it is a mere marker of upregulated XO activity within CHF pathophysiology. Therefore, the aim of this study was to test the effect of lowering UA by uricosuric treatment without XO inhibition on hemodynamic and metabolic characteristics of CHF. Impaired renal excretion of UA was taken into account. Methods and Results-Serum UA (SUA), urinary UA (uUA) excretion, and renal clearance test for UA (Cl UA) were measured in 82 patients with CHF. SUA was significantly increased compared with controls of similar age (control, 5.45 ±0.70 mg/dL; New York Heart Association I, 6.48±1.70 mg/dL; New York Heart Association II, 7.34±1.94 mg/dL; New York Heart Association III, 7.61 ±2.11 mg/dL; PUA. On multivariate analysis, insulin, brain natriuretic peptide (P

Original languageEnglish
Pages (from-to)73-81
Number of pages9
JournalCirculation: Heart Failure
Volume3
Issue number1
DOIs
Publication statusPublished - Jan 2010

Keywords

  • Benzbromarone
  • Chronic heart failure
  • Insulin sensitivity
  • Uric acid

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Uric acid-lowering treatment with benzbromarone in patients with heart failure a double-blind placebo-controlled crossover preliminary study'. Together they form a unique fingerprint.

Cite this